Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis Yun Qiu, Ren Mao, Bai-li Chen, Sheng-hong Zhang, Jing Guo, Yao He, Zhi-rong Zeng, Shomron Ben-Horin, Min-hu Chen Clinical Gastroenterology and Hepatology Volume 15, Issue 9, Pages 1359-1372.e6 (September 2017) DOI: 10.1016/j.cgh.2017.02.005 Copyright © 2017 AGA Institute Terms and Conditions
Figure 1 Summary of literature search and selection. Clinical Gastroenterology and Hepatology 2017 15, 1359-1372.e6DOI: (10.1016/j.cgh.2017.02.005) Copyright © 2017 AGA Institute Terms and Conditions
Figure 2 Forrest plot of meta-analysis of ADAs according to patients’ concomitant immunomodulators status (IM+ or IM-). Clinical Gastroenterology and Hepatology 2017 15, 1359-1372.e6DOI: (10.1016/j.cgh.2017.02.005) Copyright © 2017 AGA Institute Terms and Conditions
Figure 3 Forrest plot of meta-analysis of standardized “mean trough serum drug level” according to patients’ concomitant immunomodulators status (IM+ or IM-). Clinical Gastroenterology and Hepatology 2017 15, 1359-1372.e6DOI: (10.1016/j.cgh.2017.02.005) Copyright © 2017 AGA Institute Terms and Conditions
Figure 4 Begg funnel plot for publication bias. Studies (circles) within the projected 95% CI (diagonal lines) should have complementary areas on the opposite side of the solid line (estimated risk ratio). Gaps in the funnel patterns indicate possible areas of publication bias. Clinical Gastroenterology and Hepatology 2017 15, 1359-1372.e6DOI: (10.1016/j.cgh.2017.02.005) Copyright © 2017 AGA Institute Terms and Conditions
Supplementary Figure 1 Assessment of quality of randomized controlled trials using Cochrane risk of bias tool. Clinical Gastroenterology and Hepatology 2017 15, 1359-1372.e6DOI: (10.1016/j.cgh.2017.02.005) Copyright © 2017 AGA Institute Terms and Conditions
Supplementary Figure 2 Forrest plot of meta-analysis of weighted “mean trough serum drug level” according to patients’ concomitant immunomodulators status (IM+ or IM-). Clinical Gastroenterology and Hepatology 2017 15, 1359-1372.e6DOI: (10.1016/j.cgh.2017.02.005) Copyright © 2017 AGA Institute Terms and Conditions
Supplementary Figure 3 Forrest plot of meta-analysis of “mean trough serum drug level” according to concurrent ADAs (ADA + or ADA-). Clinical Gastroenterology and Hepatology 2017 15, 1359-1372.e6DOI: (10.1016/j.cgh.2017.02.005) Copyright © 2017 AGA Institute Terms and Conditions